Coherus BioSciences (CHRS) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.02 --0%
EPS Growth %: +39.4%
Financial Fact:
Gross profit: 261.73M
Today's EPS Names:
SICP, MNSB, CFFI, More
EPS Growth %: +39.4%
Financial Fact:
Gross profit: 261.73M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.34), in-line with the analyst estimate of ($0.34). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $14.16 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Spotify (SPOT) Misses Q3 EPS by 36c; misses on guidance
- Getty Realty (GTY) Tops Q3 EPS by 5c
- UBS Downgrades Carrefour SA (CA:FP) (CRRFY) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
